We then assessed the association of SYK with the therapeutic response to c-Metis, EGFRis, and other kinase inhibitors for the treatment of NSCLC, such as ALKis and RET inhibitors (RETis), in 15 cancer cell lines (Fig. 1f and Supplementary Table S2). Here, SYK is linked to cancer.